Hiroki Hara - Concepedia

Author

Hiroki Hara

Saitama Cancer Center ORCID

Also Known As

H Hara, H. Hara, H. James Hara, HIROKI HARA, Hamza Hara, Hara Hiroki, Hiroki HARA, Hiroki Hara, Sharon Pelles Avraham

473

Publications

15.1K

Citations

H-Index

111

Concepts

All Affiliations

Saitama Cancer Center National Cancer Center Hospital East Aichi Cancer Center Shizuoka Cancer Center Japanese Foundation For Cancer Research

About

Hiroki Hara is an author at Saitama Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	56	9.6K
2	Engineering	14	16	464
3	Health Sciences	14	17	2.5K
4	Applied Physics	4	4	73
5	Biomedical Engineering	2	2	50

Hiroki Hara

127

Publications

14.5K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Barbara Burtness, Kevin J. Harrington, Richard Greil, The Lancet Neoadjuvant TherapyChemotherapy Versus CetuximabMedicinePathologyHead And Neck Cancer	2019	3K
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study Jong‐Mu Sun, Lin Shen, Manish A. Shah, The Lancet Chemotherapy Versus ChemotherapyOncologyEsophageal CancerGastrointestinal OncologyClinical Trials	2021	1.5K
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang, The Lancet Pembrolizumab Versus PaclitaxelGastrointestinal OncologyMedicineGastroenterologySurgery	2018	1.3K
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 Dung T. Le, Tae Won Kim, Eric Van Cutsem, Journal of Clinical Oncology	2019	975
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603) Shota Fukuoka, Hiroki Hara, Naoki Takahashi, Journal of Clinical Oncology	2020	887
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Sun Young Rha, Do‐Youn Oh, Patricio Yañez, The Lancet Oncology Chemotherapy Versus PlaceboGastrointestinal OncologyMedicineClinical TrialsImmune Checkpoint Inhibitor	2023	521
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial Toshihiro Kudo, Yasuo Hamamoto, Ken Kato, The Lancet Oncology Surgical OncologyEsophageal CancerNivolumab TreatmentGastrointestinal OncologyMedicine	2017	378
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, Annals of Oncology S-1 Versus GemcitabineGastrointestinal OncologyMedicineBiliary CancerPathology	2019	320
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) Narikazu Boku, Min‐Hee Ryu, Ken Kato, Annals of Oncology	2018	317
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study Lin Shen, Ken Kato, Sung‐Bae Kim, Journal of Clinical Oncology	2022	293

Page 1